Developed jointly by Sanofi and Regeneron, alirocumab (Praluent) was approved 13-3 by an FDA advisory committee.
Developed jointly by Sanofi and Regeneron, alirocumab (Praluent) was approved 13-3 by an FDA advisory committee for the long-term treatment of adult patients with primary hypercholesterolemia or mixed dyslipidemia, including patients with type 2 diabetes mellitus.
However, several committee members warned about the cardiovascular (CV) effects of the drug, and discussions included whether low-density lipoprotein was indeed an appropriate surrogate for CV outcomes. The deputy director of the FDA's Division of Metabolism and Endocrinology, cautioned that if a decision was made to approve the drug, the agency would not require further assessments of cardiovascular outcomes. He therefore asked the panel to identify the population for whom the apparent cholesterol-lowering benefits of alirocumab could substitute for demonstrated clinical outcomes.
Alirocumab is being evaluated in a CV outcomes trial, with an expected completion date in 2017. However, if the drug was approved, panelists think patients would withdraw from the trial.
Read more on Medpage Today: http://bit.ly/1QoxJjc
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More